The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
R. S. Finn
Research Funding - Novartis
R. T. P. Poon
Consultant or Advisory Role - Novartis
T. Yau
No relevant relationships to disclose
H. Klumpen
No relevant relationships to disclose
L. Chen
Consultant or Advisory Role - Novartis (U)
Honoraria - Novartis
Research Funding - Novartis
Y. Kang
Consultant or Advisory Role - Bayer; Novartis
Research Funding - Bayer; Novartis
T. Kim
Research Funding - Clinical Trial Budget
C. Gomez-Martin
No relevant relationships to disclose
C. Rodriguez-Lope
No relevant relationships to disclose
T. Kunz
Employment or Leadership Position - Novartis
T. Paquet
Employment or Leadership Position - Novartis
K. Asubonteng
Employment or Leadership Position - Novartis
R. E. Winkler
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
O. Anak
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
D. B. Sellami
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Bruix
Consultant or Advisory Role - Bayer; Novartis
Honoraria - Bayer; Novartis
Research Funding - Bayer